SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
About SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
3
Celgene
2
Eisai Inc.
2
Clinical Trials at SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
During the past decade, SPSK Nr1 Klinika Hematoo&Transpl.Szpiku conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on
average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
1995-06-01
2006-12-01
Completed
195
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
1995-09-01
2006-12-01
Completed
86
A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
2015-05-26
2017-03-31
Completed
221
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
2015-11-18
2020-12-01
Completed
113
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
2016-06-03
2021-12-27
Completed
213
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
2016-09-27
2022-05-12
Completed
152
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
2019-01-02
2027-09-28
Active, not recruiting
363
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "SPSK Nr1 Klinika Hematoo&Transpl.Szpiku"
#1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
According to Clinical.Site data, the most researched conditions in "SPSK Nr1 Klinika Hematoo&Transpl.Szpiku" are
"Hemophilia A" (3 trials), "Lymphoma, T-Cell, Cutaneous" (2 trials), "Mycosis Fungoides" (2 trials), "Myelodysplastic Syndromes" (2 trials) and "Sezary Syndrome" (2 trials). Many other conditions were trialed in "SPSK Nr1 Klinika Hematoo&Transpl.Szpiku" in a lesser frequency.
Clinical Trials Intervention Types at SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
Most popular intervention types in "SPSK Nr1 Klinika Hematoo&Transpl.Szpiku" are "Drug" (7 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Emicizumab" (2 trials), "ONTAK" (2 trials), "Azacitidine" (1 trials), "Bypassing Agents" (1 trials) and "Durvalumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
The vast majority of trials in "SPSK Nr1 Klinika Hematoo&Transpl.Szpiku" are
7 trials for "All" genders.
Clinical Trials Status at SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
Currently, there are NaN active trials in "SPSK Nr1 Klinika Hematoo&Transpl.Szpiku".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in SPSK Nr1 Klinika Hematoo&Transpl.Szpiku,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in SPSK Nr1 Klinika Hematoo&Transpl.Szpiku, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 0 trials that are defined as “Not Applicable".